SIRT1 and chronic myelogenous leukemia, BCR-ABL1 positive: SIRT1 or downstream elements of the oxidative phosphorylation pathway are potential therapeutic targets of SR-18292 (PGC-1α inhibitor), alone or in combination with TKIs, to prevent CML relapse.